{
    "clinical_study": {
        "@rank": "55466", 
        "arm_group": [
            {
                "arm_group_label": "micronized progesterone", 
                "arm_group_type": "Experimental", 
                "description": "1 mg 17 beta-estradiol plus 100 mg micronized progesterone taken orally once a day for 3 months."
            }, 
            {
                "arm_group_label": "dydrogesterone", 
                "arm_group_type": "Experimental", 
                "description": "1mg 17 beta-estradiol plus 10 mg dydrogesterone taken orally once a day for 3 months."
            }
        ], 
        "brief_summary": {
            "textblock": "Investigators have found that sleeping disorder is an important problem in menopausal women.\n\n      There have been papers reporting the effect of hormonal therapy on sleeping, but fews have\n      reported the effect of different progestogens on sleeping quality. There is a need for more\n      in-depth study and more conclusive evidence about the progestins which have the most\n      beneficial effects on sleeping disorders in menopausal women.\n\n      This study is going to collect the data from newly identified menopausal patients who are\n      eligible for continuous estrogen-progestogen therapy for their climacteric treatment. The\n      affects of the therapy will be monitored for 3 months."
        }, 
        "brief_title": "The Effect of Different Types of Progestin on Sleeping of Menopausal Women", 
        "condition": "Menopausal and Postmenopausal Disorders", 
        "detailed_description": {
            "textblock": "New patients who are eligible for hormonal therapy will be selected.\n\n      They will be allocated randomly into 2 different groups, each group being prescribed 1 of 2\n      regimens of hormonal therapy:\n\n        -  17 beta estradiol 1mg/day plus oral micronized progesterone 100mg/day\n\n        -  17 beta estradiol 1mg/day plus dydrogesterone 10mg/day Patients will have their\n           sleeping quality accessed using the Pittsburgh sleep quality index(PSQI) at their 1st\n           visit and once a month for 3 months. The first and third PSQI score will be analysed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  new menopausal patients at Maharaj Nakorn Chiang Mai Hospital\n\n          -  suitable for estrogen plus progesterone treatment\n\n        Exclusion Criteria:\n\n          -  contraindication for hormone replacement therapy\n\n          -  recently used sleep enhancing medicine\n\n          -  recently used psychotic medicine"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02086032", 
            "org_study_id": "OBG-2556-02070"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "micronized progesterone", 
                    "dydrogesterone"
                ], 
                "description": "Comparing sleeping quality between micronized progesterone and dydrogesterone users.", 
                "intervention_name": "1mg 17 beta-estradiol", 
                "intervention_type": "Drug", 
                "other_name": "Estrogen"
            }, 
            {
                "arm_group_label": "dydrogesterone", 
                "description": "Comparing sleeping quality between micronised progesterone and dydrogesterone users.", 
                "intervention_name": "Dydrogesterone", 
                "intervention_type": "Drug", 
                "other_name": "Duphaston"
            }, 
            {
                "arm_group_label": "micronized progesterone", 
                "description": "Comparing sleeping quality between micronised progesterone and dydrogesterone users", 
                "intervention_name": "micronized progesterone", 
                "intervention_type": "Drug", 
                "other_name": "Utrogestan"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dydrogesterone", 
                "Progestins", 
                "Progesterone", 
                "Estradiol", 
                "Polyestradiol phosphate", 
                "Estradiol valerate", 
                "Estradiol 3-benzoate", 
                "Estradiol 17 beta-cypionate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Sleeping quality", 
            "menopause", 
            "climacteric", 
            "progestin", 
            "dydrogesterone", 
            "micronized progesterone"
        ], 
        "lastchanged_date": "March 12, 2014", 
        "location": {
            "contact": {
                "email": "tawiwan.p@cmu.ac.th", 
                "last_name": "Tawiwan Pantasri, MD.", 
                "phone": "+66 53945552"
            }, 
            "facility": {
                "address": {
                    "city": "Muang", 
                    "country": "Thailand", 
                    "state": "Chiang Mai", 
                    "zip": "50200"
                }, 
                "name": "Obstetrics and Gynecology department, Faculty of Medicine, Chiang Mai University"
            }, 
            "investigator": {
                "last_name": "Ekachai Leeangkoonsathian, MD.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Different Types of Progestin on Sleeping of Menopausal Women", 
        "overall_official": {
            "affiliation": "Faculty of Medicine, Chiang Mai University, Thailand", 
            "last_name": "Tawiwan Pantasri, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Thailand: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Improving of sleeping quality (assessed by the PSQI score)", 
            "safety_issue": "No", 
            "time_frame": "from March 2014 up to 15 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02086032"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chiang Mai University", 
            "investigator_full_name": "Ekachai Leeangkoonsathian", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Acne,melanoma, breast tenderness, abnormal vaginal bleeding, weight change", 
                "measure": "The side effects comparing the 2 arms.", 
                "safety_issue": "No", 
                "time_frame": "from March 2014 up to 15 months"
            }, 
            {
                "description": "self reported of hot flash, fatigue and weakness", 
                "measure": "The climacteric symptoms comparing the 2 arms.", 
                "safety_issue": "No", 
                "time_frame": "from March 2014 up to 15 months"
            }
        ], 
        "source": "Chiang Mai University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiang Mai University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}